Monday - October 26, 2026
RYBREVANT FASPRO(tm) (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer
October 25, 2026
NEW BRUNSWICK, New Jersey, Oct. 25 [Category: BizHealth & Beauty] -- Johnson and Johnson posted the following news release:

* * *

RYBREVANT FASPRO(tm) (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer

*

New Brunswick, N.J. October 25, 2026 /PR Newswire/ - Johnson & Johnson (NYSE:JNJ) today announced new results from Cohort 5 of t . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Click here for more information about our products